KYMR - Kymera Therapeutics - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5015751044

Protein, Degradation, Inflammation, Cancer, Autoimmune

Kymera Therapeutics Inc., a cutting-edge biopharmaceutical company, is revolutionizing the way we tackle diseases by harnessing the body's natural protein degradation system to develop novel small molecule therapeutics. These innovative treatments selectively target and break down disease-causing proteins, offering new hope for patients worldwide.

The company is currently advancing several promising programs, including its IRAK4 program, which is in Phase II clinical trials for the treatment of debilitating immunology-inflammation diseases such as hidradenitis suppurativa and atopic dermatitis. These conditions significantly impact patients' quality of life, and Kymera's IRAK4 program aims to bring much-needed relief.

Kymera is also developing its STAT3 program to combat hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis. This program has the potential to transform the treatment landscape for these complex and often aggressive diseases. Additionally, the company's MDM2 program is focused on treating hematological malignancies and solid tumors, offering new possibilities for patients with these life-threatening conditions.

Furthermore, Kymera is exploring the potential of STAT6, a promising treatment for allergic diseases characterized by Type 2 inflammation. The company is also developing TYK2, a novel treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. These programs demonstrate Kymera's commitment to addressing significant unmet medical needs.

Founded in 2015, Kymera Therapeutics is headquartered in Watertown, Massachusetts, and is dedicated to pushing the boundaries of medical innovation. To learn more about the company's groundbreaking work, visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for KYMR - Kymera Therapeutics  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for KYMR - Kymera Therapeutics  - Stock Price & Dividends

KYMR Stock Overview

Market Cap in USD 2,393m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2020-08-21

KYMR Stock Ratings

Growth 5y 6.51
Fundamental -58.8
Dividend 0.00
Rel. Performance vs Sector 2.84
Analysts 4.12/5
Fair Price Momentum 48.88 USD
Fair Price DCF -

KYMR Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

KYMR Growth Ratios

Growth 12m 99.17%
Growth Correlation 12m 49%
Growth Correlation 3m -16%
CAGR 5y 6.84%
CAGR/Mean DD 5y 0.13
Sharpe Ratio 12m 1.28
Alpha vs SP500 12m 42.80
Beta vs SP500 5y weekly 2.88
ValueRay RSI 83.67
Volatility GJR Garch 1y 119.65%
Price / SMA 50 23%
Price / SMA 200 43.33%
Current Volume 528.4k
Average Volume 20d 869k

External Links for KYMR Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of KYMR stocks?
As of July 20, 2024, the stock is trading at USD 43.10 with a total of 528,429 shares traded.
Over the past week, the price has changed by +1.89%, over one month by +37.83%, over three months by +26.88% and over the past year by +96.80%.
What are the forecast for KYMR stock price target?
According to ValueRays Forecast Model, KYMR Kymera Therapeutics will be worth about 56.6 in July 2025. The stock is currently trading at 43.10. This means that the stock has a potential upside of +31.25%.
Issuer Forecast Upside
Wallstreet Target Price 51.4 19.3
Analysts Target Price 56.5 31.2
ValueRay Target Price 56.6 31.3